Immune regulation of procalcitonin: a biomarker and mediator of infection

被引：92

作者：

Matwiyoff, G. N. ^{[1
]}

Prahl, J. D. ^{[1
]}

Miller, R. J. ^{[1
]}

Carmichael, J. J. ^{[1
]}

Amundson, D. E. ^{[2
]}

Seda, G. ^{[1
]}

Daheshia, M. ^{[1
]}

机构：

[1] USN, Dept Pulm Med, Med Ctr San Diego, San Diego, CA 92134 USA

[2] Scripps Mem Hosp, Dept Crit Care, Encinitas, CA 92024 USA

来源：

INFLAMMATION RESEARCH | 2012年 / 61卷 / 05期

关键词：

Procalcitonin; Biomarker; Inflammation; Regulation; Infection; C-REACTIVE PROTEIN; GENE-RELATED PEPTIDE; CALCITONIN-I GENE; CIRCULATING BLOOD-CELLS; CRITICALLY-ILL PATIENTS; SERUM PROCALCITONIN; SEVERE SEPSIS; SYSTEMIC INFLAMMATION; BACTERIAL-INFECTION; CYTOKINE RESPONSE;

D O I：

10.1007/s00011-012-0439-5

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Procalcitonin (PCT) has recently emerged as a powerful biomarker for an early and accurate diagnosis of bacterial infection. Here we summarize our current understanding of the expression pathways of PCT, its potential cellular sources including immune cells, and factors inducing its secretion. Also addressed is the significance of increased blood PCT concentration, which may allow this molecule not only to act as a clinical biomarker but also as an active participant in the development and progression of infectious processes. Experimental approaches to delineate a better understanding of PCT functions, molecular pathways that modulate its expression and therapeutic opportunities to curtail its biological actions are discussed, as well.

引用

页码：401 / 409

页数：9

共 80 条

[1]

Abbasi A., 2011, Diabetologia

[2] Procalcitonin in patients with and without immunosuppression and sepsis [J].

AlNawas, B ;

Shah, PM .

INFECTION, 1996, 24 (06) :434-436

[3]

[Anonymous], SUPPORT CARE CANC

[4] HIGH SERUM PROCALCITONIN CONCENTRATIONS IN PATIENTS WITH SEPSIS AND INFECTION [J].

ASSICOT, M ;

GENDREL, D ;

CARSIN, H ;

RAYMOND, J ;

GUILBAUD, J ;

BOHUON, C .

LANCET, 1993, 341 (8844) :515-518

[5] Procalcitonin as a marker for severe sepsis in an immunosuppressed patient [J].

Axer, H ;

Wohlfarth, M ;

Meisner, M ;

Finn, S ;

Ragoschke-Schumm, A ;

Mentzel, HJ ;

Witte, OW ;

Isenmann, S .

ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 2005, 40 (02) :97-102

[6] Flow cytometric analysis of procalcitonin expression in human monocytes and granulocytes [J].

Balog, A ;

Ocsovszki, I ;

Mándi, Y .

IMMUNOLOGY LETTERS, 2002, 84 (03) :199-203

[7] Comparison of WBC, ESR, CRP and PCT serum levels in septic and non-septic burn cases [J].

Barati, Mitra ;

Alinejad, Faranak ;

Bahar, Mohammad Ali ;

Tabrisi, Mahbobe Satarzadeh ;

Shamshiri, Ahmad Reza ;

Bodouhi, Nosrat-ol-lahe ;

Karimi, Hamid .

BURNS, 2008, 34 (06) :770-774

[8] Procalcitonin in sepsis and systemic inflammation: a harmful biomarker and a therapeutic target [J].

Becker, Kenneth L. ;

Snider, Richard ;

Nylen, Eric S. .

BRITISH JOURNAL OF PHARMACOLOGY, 2010, 159 (02) :253-264

[9] STUDY OF CALCITONIN HETEROGENEITY USING A RADIORECEPTOR ASSAY [J].

BECKER, KL ;

BIVINS, LE ;

RADFAR, RH ;

SNIDER, RH ;

MOORE, CF ;

SILVA, OL .

HORMONE AND METABOLIC RESEARCH, 1978, 10 (05) :457-458

[10]

Bolko P, 2003, ARCH IMMUNOL THER EX, V51, P415

← 1 2 3 4 5 6 7 8 →